Results 261 to 270 of about 5,994,707 (387)

Structural Basis for D3/D4-Selective Antagonism of Piperazinylalkyl Pyrazole/Isoxazole Analogs. [PDF]

Molecules
Choi KE, Jang SH, Park WK, No KT, Koh HY, Pae AN, Cho NC.   +6 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Cardiovascular Effects of Cannabidiol: From Molecular Mechanisms to Clinical Implementation. [PDF]

Int J Mol Sci
Urlić H, Kumrić M, Pavlović N, Dujić G, Dujić Ž, Božić J.   +5 more
europepmc   +1 more source

Affinity labeling of the acetylcholine-receptor.

, 1967
Jean‐Pierre Changeux, Thomas R. Podleski, Leon Wofsy   +2 more
openalex   +1 more source

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.

Journal of Clinical Investigation, 2006
T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, K. Tobe   +5 more
semanticscholar   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

The endocannabinoid system as a therapeutic target in intestinal fibrosis. [PDF]

Front Pharmacol
Misztal Z, Kaśniewska-Kosińska A, Wołyniak M, Małecka-Wojciesko E, Fabisiak A.   +4 more
europepmc   +1 more source

Stimulation of the Labellar Sugar Receptor of the Fleshfly by Mono- and Disaccharides

, 1968
Hiromichi Morita, Akio Shiraishi
openalex   +2 more sources

Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1

Journal of Immunology, 2009
F. Bauernfeind, Gabor L Horvath, A. Stutz, E. Alnemri, K. MacDonald, D. Speert, T. Fernandes‐Alnemri, Jianghong Wu, Brian G. Monks, K. Fitzgerald, V. Hornung, E. Latz   +11 more
semanticscholar   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source